OnCo
technologiesTechnologyStandard of care

PSMA PET

A prostate-cancer-specific PET scan that finds spread far earlier than CT or bone scan, and tells you whether a matched radioactive drug will work.

68Ga-PSMA-11 (Illuccix, Locametz), 18F-DCFPyL (Pylarify, and Pylarify TruVu approved March 2026), and 18F-rhPSMA-7.3 (Posluma) are approved. Standard for initial staging of high-risk disease and biochemical recurrence; required to select patients for 177Lu-PSMA-617 (VISION, PSMAfore).

Schematic · not to scale
Detector ring · PSMA ligand · 511 keV photon pair

How it works

Small-molecule urea-based ligands bind PSMA's active site and are internalised.

Strengths
  • Detects recurrence at PSA <0.5 ng/mL
  • Theranostic gatekeeper
Limitations
  • PSMA-negative disease in ~10%
  • Uptake in ganglia, salivary glands
Since
2020

Products

5top

Key papers

1top

Latest papers

top
Literature trend639 papers in the last 12 months+24% vs prior 12How this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"PSMA PET" OR ABSTRACT:"PSMA PET" OR TITLE:"PSMA PET/CT" OR ABSTRACT:"PSMA PET/CT" OR TITLE:"68Ga-PSMA" OR ABSTRACT:"68Ga-PSMA" OR TITLE:"18F-DCFPyL" OR ABSTRACT:"18F-DCFPyL"). Results are unfiltered search hits about PSMA PET, not a curated reading list.

Connected

58top

Pages like this

not linked directly; found by shared links

cancers

1

fronts

2

technologies

5

targets

1

drugs

5

companies

1

institutions

17

pathways

1

terms

4

trials

3

pairings

1

roadmaps

2

ideas

4

collections

1

people

8

bottlenecks

1

key papers

1